Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2‐positive patients undergoing neoadjuvant therapy: A single‐institution retrospective cohort

Documenti analoghi

• p95HER2 expression in HER2‐positive breast cancer with primary resistance
  di: Chih Wan Goh, et al.
  Pubblicazione: (2024)
• XBP1s Mediates Cross‐resistance to Combination Treatment of CDK4/6 Inhibitors plus Endocrine Therapy in Breast Cancer
  di: Yuting Sang, et al.
  Pubblicazione: (2025)
• Somatic co‐alteration signatures are prognostic in high‐grade TP53‐mutated myeloid neoplasms
  di: Emily O. Symes, et al.
  Pubblicazione: (2024)
• LINC01235 Promotes Clonal Evolution through DNA Replication Licensing‐Induced Chromosomal Instability in Breast Cancer
  di: Qi Zhang, et al.
  Pubblicazione: (2025)
• TP53 and KMT2D mutations associated with worse prognosis in peripheral T‐cell lymphomas
  di: Lingling Wang, et al.
  Pubblicazione: (2024)